

Anti-TNFSF5/CD40L/CD154 Antibody (Toralizumab)

Introduction

Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) composed of a human gamma 1 heavy chain and a human kappa light chain. Toralizumab specifically binds to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab is an immunosuppressant with potential for use in active systemic lupus erythematosus (SLE) research.

Product parameters

Alternative Names	IDEC-131, E6040
Target Accession	P29965
Target	TNFSF5 / CD40L / CD154
CAS number	252662-47-8
Molecular Weight	145.66 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	-
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

